Companies / Israel
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Threats, Opportunities Await R&D Firms
September 2006 | BMI ViewSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Israel represents the most advanced pharmaceuticals sector in the Middle East. At US$179, annual per capita pharmaceutical spending is the highest in the region. The market is dominated by institutions, with the four main 'not-for-profit' healthcare/sick funds accounting for over 80% of sales. Pharmacies and government bodies represent the remainder. Generics giant Teva's continuing strong performance will drive industry growth in the short term, as will the expansion of the biotech industry. However, government cost-containment measures are having a negative impact. Growth in generics is likely to outstrip the prescription market, and the sector is expected to account for some